Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K11 | Q16584 | 1/20 | 0.43 |
| ▸ | AR | P10275 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | DRD4 | P21917 | 1/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.38 |
| ▸ | CRBN | Q96SW2 | 4/20 | 0.38 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.38 |
| ▸ | PGR | P06401 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | PARG | Q86W56 | 1/20 | 0.35 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.34 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.34 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.34 |
| ▸ | HTR7 | P34969 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.34 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24405711 | 0.90 | OPRM1 (0.43) | MAP3K11ARCRBNDDB1PGR | |
| SCHEMBL24405379 | 0.82 | HTR6 (0.48) | — | |
| SCHEMBL15082034 | 0.75 | NOTUM (0.39) | ARDRD2CRBNDDB1PGR | |
| SCHEMBL12045447 | 0.74 | MAP3K11 (0.38) | MAP3K11ARDRD2DRD4CYP11B2 | |
| SCHEMBL1997957 | 0.73 | CYP11B2 (0.44) | MAP3K11ARDRD2DRD4CYP11B2 | |
| SCHEMBL24405587 | 0.73 | PGR (0.39) | CRBNDDB1PGRPARGHTR7 | |
| SCHEMBL14209166 | 0.72 | DRD2 (0.49) | MAP3K11DRD2DRD4CYP11B2ALDH1A1 | |
| SCHEMBL1701903 | 0.72 | MAP3K11 (0.42) | MAP3K11ARDRD2DRD4CYP11B2 | |
| SCHEMBL9980855 | 0.72 | MAP3K11 (0.42) | MAP3K11ARCYP11B2CRBNPGR | |
| SCHEMBL2700854 | 0.71 | KMT2A (0.47) | DRD2DRD4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9226921-B2 | Fused heterocyclic compounds as phosphodiesterases (PDES) inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-01-05 | — | — | US | disclosed |
| US-8846713-B2 | Fused heterocyclic compounds as phosphodiesterases (PDEs) inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-09-30 | — | — | US | disclosed |
| US-20140228320-A1 | FUSED HETEROCYCLIC COMPOUNDS AS PHOSPHODIESTERASES (PDES) INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-08-14 | — | — | US | disclosed |
| US-8563575-B2 | Fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-10-22 | — | — | US | disclosed |
| US-20130172328-A1 | FUSED HETEROCYCLIC COMPOUNDS AS PHOSPHODIESTERASES (PDES) INHIBITORS | CROSSWING INC. (CA) | 2013-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130172328-A1 | FUSED HETEROCYCLIC COMPOUNDS AS PHOSPHODIESTERASES (PDES) INHIBITORS | PDE3A, PDE5A, PDE2A | MAP3K11 1766/4885AR 3138/4885DRD2 684/4885 |
| US-20140228320-A1 | FUSED HETEROCYCLIC COMPOUNDS AS PHOSPHODIESTERASES (PDES) INHIBITORS | PDE3A, PDE5A, PDE2A | MAP3K11 1766/4885AR 3138/4885DRD2 684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.